We have located links that may give you full text access.
Journal Article
Review
[PD-1/PD-L1 Signaling Pathway and Its Anti-Tumor Effect in Lymphoma -Review].
Zhongguo Shi Yan Xue Ye Xue za Zhi 2018 June
In tumor patients, programmed cell death-1 (PD-1) can inhibit T-cell activation and proliferation by binding to its ligand, thereby promote tumor immune escape. A large number of experiments showed that PD-L1 molecule highly expressed on lymphoma cells, while PD-1 expression was up-regulated in tumor-infiltrating lymphocytes, suggesting its role in the development of lymphoma, which may be an important therapeutic target for lymphoma. PD-1 and PD-L1 monoclonal antibodies can block the PD-1 / PD-Ls signaling pathway, restore T cell function, thus inhibit the tumor growth. At present, a number of early clinical trials have demonstrated the significant efficacy and less side effects in various subtypes of recurrent lymphoma, which will be promising therapeutic agents. In this review, the mechanism of PD-1/PD-L1 signal pathway, the expression of PD-1 / PD-L1 in lymphoma and the anti-tumor effect of its antibody in lymphoma are summarized.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app